Abbisko Therapeutics
Abbisko is a Shanghai biotech listed in Hong Kong whose CSF-1R inhibitor pimicotinib met its phase 3 endpoint in tenosynovial giant cell tumour, a rare joint tumour, and is licensed to Merck KGaA.
Overview
Abbisko Therapeutics, based in Shanghai and listed in Hong Kong, develops small-molecule kinase inhibitors. Its lead drug pimicotinib (ABSK021), a selective CSF-1R inhibitor, met the primary endpoint of the phase 3 MANEUVER trial in tenosynovial giant cell tumour and is partnered with Merck KGaA outside China; FGFR4 and pan-FGFR inhibitors follow in liver and urothelial cancer. Its trials are registered on ClinicalTrials.gov under Abbisko as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyAscletis Pharma
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyCan-Fite BioPharma
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyGC Cell
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyImmunitor
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyThreshold Pharmaceuticals
Shares Merck KGaA (EMD Serono), Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.